유전자 침묵 치료 시장 보고서(2026년)

Gene silencing therapeutics are treatments that work by reducing, blocking, or turning off the expression of specific disease-causing genes to prevent the production of harmful proteins in the body. These therapies use advanced molecular technologies to target messenger RNA (mRNA) before defective proteins are produced. Gene silencing therapeutics are widely used in the treatment of various conditions by selectively regulating abnormal gene activity.

The primary technologies of gene silencing therapeutics include ribonucleic acid interference, antisense oligonucleotides, clustered regularly interspaced short palindromic repeats-associated protein 9, and other technologies. Ribonucleic acid interference refers to a gene regulation mechanism that suppresses the expression of specific genes by targeting and degrading messenger RNA molecules. These therapeutics utilize delivery methods including nanoparticles, viral vectors, liposomes, and other delivery methods. The key applications include oncology, genetic disorders, infectious diseases, neurological disorders, and others, while the end-users include hospitals, research institutes, and pharmaceutical and biotechnology companies.

Tariffs are influencing the gene silencing therapeutics market by increasing the cost of imported oligonucleotides, gene editing materials, laboratory reagents, delivery system components, and specialized biomanufacturing equipment required for therapeutic development and production. This is raising research, clinical trial, and manufacturing expenses, particularly across RNA interference, antisense oligonucleotide, and CRISPR-associated technology segments. Regions heavily dependent on global biotechnology supply chains, including Asia-Pacific and Europe, are experiencing procurement challenges and cost pressures. However, tariffs are also encouraging domestic biotechnology manufacturing, regional supplier diversification, and increased investment in local research and production infrastructure, creating long-term resilience in the market.

The gene silencing therapeutics market size has grown rapidly in recent years. It will grow from $4 billion in 2025 to $4.64 billion in 2026 at a compound annual growth rate (CAGR) of 16.1%. The growth in the historic period can be attributed to growing prevalence of genetic disorders, increasing investment in molecular medicine research, rising demand for targeted therapeutic approaches, expanding clinical success of RNA based therapies, increasing focus on rare disease treatment development.

The gene silencing therapeutics market size is expected to see rapidly grown in the next few years. It will grow to $8.49 billion in 2030 at a compound annual growth rate (CAGR) of 16.3%. The growth in the forecast period can be attributed to advancing commercialization of gene silencing therapeutics, growing pipeline of precision genetic medicines, increasing regulatory approvals for novel gene therapies, expanding application across oncology and neurological disorders, rising adoption of personalized medicine strategies. Major trends in the forecast period include increasing adoption of RNA interference based therapeutics, growing development of antisense oligonucleotide treatment platforms, rising focus on targeted gene expression regulation for rare diseases, expansion of advanced delivery technologies for gene silencing therapeutics, increasing clinical research activity in next generation gene silencing therapies.

The growing focus on personalized medicine is expected to propel the growth of the gene silencing therapeutics market going forward. Personalized medicine refers to a healthcare approach that customizes medical treatment based on an individual's genetic profile, biomarkers, and specific disease characteristics to enhance treatment effectiveness and clinical outcomes. The increasing focus on personalized medicine is driven by advancements in genetic and molecular profiling technologies that enable tailored treatments based on individual patient characteristics. Gene-silencing therapeutics support personalized medicine by selectively targeting disease-causing genes based on an individual's genetic profile, enabling more precise treatment with improved effectiveness and fewer side effects. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based nonprofit organization, in 2023, the FDA approved 16 new personalized treatments for rare disease patients, up from six in 2022. Therefore, the growing adoption of personalized medicine is driving the growth of the gene silencing therapeutics market.

Major companies operating in the gene silencing therapeutics market are adopting advanced RNA delivery platforms, such as ligand-conjugated siRNA technologies, to improve tissue-specific targeting and enhance therapeutic precision for genetic and renal diseases. Ligand-conjugated siRNA technologies refer to specialized RNA delivery approaches that attach targeting ligands to small interfering RNA molecules to enable receptor-mediated uptake and selective gene silencing in specific tissues or cell types. For instance, in June 2025, Judo Bio, Inc., a US-based biotechnology company, launched with $100 million in Series A financing led by Atlas Venture, TCG, and Droia Ventures to advance precision genetic medicines targeting kidney diseases. The company introduced its STRIKE (Selectively Targeting RNA Into Kidney) platform, a ligand-conjugated siRNA delivery technology engineered for receptor-mediated uptake into kidney cell types, enabling selective gene silencing in renal tissues. The platform's initial megalin-STRIKER programs are designed to deliver small interfering RNA therapeutics to proximal tubule cells in the kidney to silence mRNA expression of solute carrier proteins associated with systemic and renal diseases.

In July 2023, Novartis AG, a Switzerland-based pharmaceutical company, acquired DTx Pharma Inc. for an undisclosed amount. Through this acquisition, Novartis AG aimed to strengthen its gene silencing therapeutics pipeline by integrating DTx Pharma Inc.'s proprietary FALCON RNA delivery platform to expand the development of RNAi-based therapies for neurological and neuromuscular diseases. DTx Pharma Inc. is a US-based biotechnology company specializing in RNA-based therapeutics, particularly small interfering RNA (siRNA) technologies designed to silence disease-causing genes.

Major companies operating in the gene silencing therapeutics market are Novartis AG; Alnylam Pharmaceuticals Inc.; Ionis Pharmaceuticals Inc.; Sarepta Therapeutics Inc.; Arrowhead Pharmaceuticals Inc.; Silence Therapeutics plc; Wave Life Sciences Ltd.; ProQR Therapeutics N.V.; Dyne Therapeutics Inc.; Stoke Therapeutics Inc.; Arbutus Biopharma Corporation; PepGen Inc.; Sirnaomics Ltd.; OliX Pharmaceuticals Inc.; Benitec Biopharma Inc.; ADARx Pharmaceuticals Inc.; Tune Therapeutics Inc.; Sylentis S.A.; Isarna Therapeutics GmbH; City Therapeutics Inc.; Arcturus Therapeutics Holdings Inc.; Novo Nordisk; Moderna Inc.; BioNTech SE; Sanofi

North America was the largest region in the gene silencing therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gene silencing therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the gene silencing therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The gene silencing therapeutics market consists of revenues earned by entities by providing services such as RNA interference (RNAi) therapy development, antisense oligonucleotide therapy services, gene expression suppression solutions, target gene validation, therapeutic RNA design, drug delivery optimization, clinical development services, and precision medicine support. The market value includes the value of related goods sold by the service provider or included within the service offering. The gene silencing therapeutics market also includes sales of microfluidic delivery systems, electroporation devices, lipid nanoparticle formulation equipment, and automated nucleic acid synthesizers. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The gene silencing therapeutics market research report is one of a series of new reports from The Business Research Company that provides gene silencing therapeutics market statistics, including gene silencing therapeutics industry global market size, regional shares, competitors with a gene silencing therapeutics market share, detailed gene silencing therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the gene silencing therapeutics industry. This gene silencing therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Gene Silencing Therapeutics Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses gene silencing therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for gene silencing therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The gene silencing therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Technology: Ribonucleic Acid Interference; Antisense Oligonucleotides; Other Technologies
• 2) By Delivery Method: Nanoparticles; Viral Vectors; Liposomes; Other Delivery Methods
• 3) By Application: Oncology; Genetic Disorders; Infectious Diseases; Neurological Disorders; Other Applications
• 4) By End User: Hospitals; Research Institutes; Pharmaceutical And Biotechnology Companies; Other End Users
• Subsegments:
• 1) By Ribonucleic Acid Interference: Small Interfering Ribonucleic Acid Therapeutics; Short Hairpin Ribonucleic Acid Therapeutics; Micro Ribonucleic Acid Therapeutics; Dicer Substrate Small Interfering Ribonucleic Acid Therapeutics
• 2) By Antisense Oligonucleotides: Exon Skipping Oligonucleotides; Splice Switching Oligonucleotides; Gapmer Antisense Oligonucleotides; Phosphorothioate Oligonucleotides; Peptide Conjugated Oligonucleotides
• 3) By Other Technologies: Aptamer Based Gene Silencing; Zinc Finger Nuclease Technologies; Transcription Activator Like Effector Nuclease Based Gene Silencing; Messenger Ribonucleic Acid Degradation Technologies; Epigenetic Gene Silencing Technologies
• Companies Mentioned: Novartis AG; Alnylam Pharmaceuticals Inc.; Ionis Pharmaceuticals Inc.; Sarepta Therapeutics Inc.; Arrowhead Pharmaceuticals Inc.; Silence Therapeutics plc; Wave Life Sciences Ltd.; ProQR Therapeutics N.V.; Dyne Therapeutics Inc.; Stoke Therapeutics Inc.; Arbutus Biopharma Corporation; PepGen Inc.; Sirnaomics Ltd.; OliX Pharmaceuticals Inc.; Benitec Biopharma Inc.; ADARx Pharmaceuticals Inc.; Tune Therapeutics Inc.; Sylentis S.A.; Isarna Therapeutics GmbH; City Therapeutics Inc.; Arcturus Therapeutics Holdings Inc.; Novo Nordisk; Moderna Inc.; BioNTech SE; Sanofi
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Gene Silencing Therapeutics Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Gene Silencing Therapeutics Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Gene Silencing Therapeutics Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Gene Silencing Therapeutics Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Artificial Intelligence & Autonomous Intelligence
  • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.4 Industry 4.0 & Intelligent Manufacturing
  • 4.1.5 Internet of Things (IoT), Smart Infrastructure & Connected Ecosystems
• 4.2. Major Trends
  • 4.2.1 Increasing Adoption Of RNA Interference Based Therapeutics
  • 4.2.2 Growing Development Of Antisense Oligonucleotide Treatment Platforms
  • 4.2.3 Rising Focus On Targeted Gene Expression Regulation For Rare Diseases
  • 4.2.4 Expansion Of Advanced Delivery Technologies For Gene Silencing Therapeutics
  • 4.2.5 Increasing Clinical Research Activity In Next Generation Gene Silencing Therapies

5. Gene Silencing Therapeutics Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Research Institutes
• 5.3 Pharmaceutical And Biotechnology Companies
• 5.4 Contract Research Organizations
• 5.5 Other End Users

6. Gene Silencing Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Gene Silencing Therapeutics Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Gene Silencing Therapeutics PESTEL Analysis (Political, Economical, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Gene Silencing Therapeutics Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Gene Silencing Therapeutics Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Gene Silencing Therapeutics Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Gene Silencing Therapeutics Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Gene Silencing Therapeutics Market Segmentation

• 9.1. Global Gene Silencing Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Ribonucleic Acid Interference, Antisense Oligonucleotides, Other Technologies
• 9.2. Global Gene Silencing Therapeutics Market, Segmentation By Delivery Method, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Nanoparticles, Viral Vectors, Liposomes, Other Delivery Methods
• 9.3. Global Gene Silencing Therapeutics Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Oncology, Genetic Disorders, Infectious Diseases, Neurological Disorders, Other Applications
• 9.4. Global Gene Silencing Therapeutics Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospitals, Research Institutes, Pharmaceutical And Biotechnology Companies, Other End Users
• 9.5. Global Gene Silencing Therapeutics Market, Sub-Segmentation Of Ribonucleic Acid Interference, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Small Interfering Ribonucleic Acid Therapeutics, Short Hairpin Ribonucleic Acid Therapeutics, Micro Ribonucleic Acid Therapeutics, Dicer Substrate Small Interfering Ribonucleic Acid Therapeutics
• 9.6. Global Gene Silencing Therapeutics Market, Sub-Segmentation Of Antisense Oligonucleotides, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Exon Skipping Oligonucleotides, Splice Switching Oligonucleotides, Gapmer Antisense Oligonucleotides, Phosphorothioate Oligonucleotides, Peptide Conjugated Oligonucleotides
• 9.7. Global Gene Silencing Therapeutics Market, Sub-Segmentation Of Other Technologies, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Aptamer Based Gene Silencing, Zinc Finger Nuclease Technologies, Transcription Activator Like Effector Nuclease Based Gene Silencing, Messenger Ribonucleic Acid Degradation Technologies, Epigenetic Gene Silencing Technologies

10. Gene Silencing Therapeutics Market Regional And Country Analysis

• 10.1. Global Gene Silencing Therapeutics Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Gene Silencing Therapeutics Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Gene Silencing Therapeutics Market

• 11.1. Asia-Pacific Gene Silencing Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Gene Silencing Therapeutics Market, Segmentation By Technology, Segmentation By Delivery Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Gene Silencing Therapeutics Market

• 12.1. China Gene Silencing Therapeutics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Gene Silencing Therapeutics Market, Segmentation By Technology, Segmentation By Delivery Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Gene Silencing Therapeutics Market

• 13.1. India Gene Silencing Therapeutics Market, Segmentation By Technology, Segmentation By Delivery Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Gene Silencing Therapeutics Market

• 14.1. Japan Gene Silencing Therapeutics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Gene Silencing Therapeutics Market, Segmentation By Technology, Segmentation By Delivery Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Gene Silencing Therapeutics Market

• 15.1. Australia Gene Silencing Therapeutics Market, Segmentation By Technology, Segmentation By Delivery Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Gene Silencing Therapeutics Market

• 16.1. Indonesia Gene Silencing Therapeutics Market, Segmentation By Technology, Segmentation By Delivery Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Gene Silencing Therapeutics Market

• 17.1. South Korea Gene Silencing Therapeutics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Gene Silencing Therapeutics Market, Segmentation By Technology, Segmentation By Delivery Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Gene Silencing Therapeutics Market

• 18.1. Taiwan Gene Silencing Therapeutics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Gene Silencing Therapeutics Market, Segmentation By Technology, Segmentation By Delivery Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Gene Silencing Therapeutics Market

• 19.1. South East Asia Gene Silencing Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Gene Silencing Therapeutics Market, Segmentation By Technology, Segmentation By Delivery Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Gene Silencing Therapeutics Market

• 20.1. Western Europe Gene Silencing Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Gene Silencing Therapeutics Market, Segmentation By Technology, Segmentation By Delivery Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Gene Silencing Therapeutics Market

• 21.1. UK Gene Silencing Therapeutics Market, Segmentation By Technology, Segmentation By Delivery Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Gene Silencing Therapeutics Market

• 22.1. Germany Gene Silencing Therapeutics Market, Segmentation By Technology, Segmentation By Delivery Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Gene Silencing Therapeutics Market

• 23.1. France Gene Silencing Therapeutics Market, Segmentation By Technology, Segmentation By Delivery Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Gene Silencing Therapeutics Market

• 24.1. Italy Gene Silencing Therapeutics Market, Segmentation By Technology, Segmentation By Delivery Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Gene Silencing Therapeutics Market

• 25.1. Spain Gene Silencing Therapeutics Market, Segmentation By Technology, Segmentation By Delivery Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Gene Silencing Therapeutics Market

• 26.1. Eastern Europe Gene Silencing Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Gene Silencing Therapeutics Market, Segmentation By Technology, Segmentation By Delivery Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Gene Silencing Therapeutics Market

• 27.1. Russia Gene Silencing Therapeutics Market, Segmentation By Technology, Segmentation By Delivery Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Gene Silencing Therapeutics Market

• 28.1. North America Gene Silencing Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Gene Silencing Therapeutics Market, Segmentation By Technology, Segmentation By Delivery Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Gene Silencing Therapeutics Market

• 29.1. USA Gene Silencing Therapeutics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Gene Silencing Therapeutics Market, Segmentation By Technology, Segmentation By Delivery Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Gene Silencing Therapeutics Market

• 30.1. Canada Gene Silencing Therapeutics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Gene Silencing Therapeutics Market, Segmentation By Technology, Segmentation By Delivery Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Gene Silencing Therapeutics Market

• 31.1. South America Gene Silencing Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Gene Silencing Therapeutics Market, Segmentation By Technology, Segmentation By Delivery Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Gene Silencing Therapeutics Market

• 32.1. Brazil Gene Silencing Therapeutics Market, Segmentation By Technology, Segmentation By Delivery Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Gene Silencing Therapeutics Market

• 33.1. Middle East Gene Silencing Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Gene Silencing Therapeutics Market, Segmentation By Technology, Segmentation By Delivery Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Gene Silencing Therapeutics Market

• 34.1. Africa Gene Silencing Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Gene Silencing Therapeutics Market, Segmentation By Technology, Segmentation By Delivery Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Gene Silencing Therapeutics Market Regulatory and Investment Landscape

36. Gene Silencing Therapeutics Market Competitive Landscape And Company Profiles

• 36.1. Gene Silencing Therapeutics Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Gene Silencing Therapeutics Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Gene Silencing Therapeutics Market Company Profiles
  • 36.3.1. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Alnylam Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Ionis Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Sarepta Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Arrowhead Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis

37. Gene Silencing Therapeutics Market Other Major And Innovative Companies

• Silence Therapeutics plc, Wave Life Sciences Ltd., ProQR Therapeutics N.V., Dyne Therapeutics Inc., Stoke Therapeutics Inc., Arbutus Biopharma Corporation, PepGen Inc., Sirnaomics Ltd., OliX Pharmaceuticals Inc., Benitec Biopharma Inc., ADARx Pharmaceuticals Inc., Tune Therapeutics Inc., Sylentis S.A., Isarna Therapeutics GmbH, City Therapeutics Inc.

38. Global Gene Silencing Therapeutics Market Competitive Benchmarking And Dashboard

39. Upcoming Startups in the Market

40. Key Mergers And Acquisitions In The Gene Silencing Therapeutics Market

41. Gene Silencing Therapeutics Market High Potential Countries, Segments and Strategies

• 41.1 Gene Silencing Therapeutics Market In 2030 - Countries Offering Most New Opportunities
• 41.2 Gene Silencing Therapeutics Market In 2030 - Segments Offering Most New Opportunities
• 41.3 Gene Silencing Therapeutics Market In 2030 - Growth Strategies
  • 41.3.1 Market Trend Based Strategies
  • 41.3.2 Competitor Strategies

42. Appendix

• 42.1. Abbreviations
• 42.2. Currencies
• 42.3. Historic And Forecast Inflation Rates
• 42.4. Research Inquiries
• 42.5. The Business Research Company
• 42.6. Copyright And Disclaimer